Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection

Salim, Farah Bokharaei; Keyvani, Hossein; Amiri, Ali; Sefidi, Fatemeh Jahanbakhsh; Shakeri, Ramin; Zamani, Farhad

doi:10.3748/wjg.v16.i16.2005

Cited by 28 publications

(32 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Flaviviridae ailesi Hepacivirüs cinsinde yer alan hepatit C virüsü (HCV), hem akut hem de kronik hepatit enfeksiyonlarına neden olmaktadır (1,2). Enfeksiyonun kronikleşme oranının yüksek olması ve virüsün uzun süre persistansı, hastalarda karaciğer yetmezliği, siroz ve hepatosellüler karsinomaya yol açabilir (1).…”

Section: Introductionunclassified

“…Enfeksiyonun kronikleşme oranının yüksek olması ve virüsün uzun süre persistansı, hastalarda karaciğer yetmezliği, siroz ve hepatosellüler karsinomaya yol açabilir (1). Kronik HCV enfeksiyonu dünya çapında önemli bir sağlık sorunu olmayı sürdürmekte, her yıl 250,000 ile 350,000 kişinin ölüme neden olmaktadır (1,3,4).…”

Section: Introductionunclassified

“…Tedaviye yanıt kriteri olarak ve tedavi süresinin belirlenmesinde HCV-RNA düzeyleri ve HCV genotipleri yol göstericidir (1).…”

Section: Introductionunclassified

“…Tüm dünyada sık olarak görülen HCV genotipleri, genotip 1a, 1b, 2a, 2b ve 3a iken genotip 4, 5 ve 6 belli bölgelerde görülmektedir (6). Genotip 1 Amerika'da, genotip 2 ve 3 Avrupa ve Japonya'da, genotip 4 Mısır ve Ortadoğu'da, genotip 5 Güney Afrika'da ve genotip 6 ise Hong Kong ve diğer Güney Doğu Asya ülkelerinde yaygın olarak bulunmaktadır (1,7). Ülkemizde yapılan çalışmalarda, dünya geneliyle benzer şekilde HCV genotip 1b'nin en yaygın genotip olduğu gösterilmistir (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17).…”

Section: Introductionunclassified

“…Son yıllarda 2007'den beri özellikle genotip 3 ve 4 daha fazla oranlarda saptanmaktadır (18)(19)(20)(21)(22)(23)(24)(25)(26). HCV genotiplendirmesi, uygun tedavinin seçilmesi, tedavinin süresinin belirlenmesinde ve uygulanan tedaviye yanıtın izlenmesinde önemlidir (1). Hepatit C enfeksiyonun Peg interferon + ribavirin ile kombine tedavisinde yanıtı belirleyen en önemli faktörler, genotip ve başlangıçtaki HCV-RNA düzeyleridir.…”

Section: Introductionunclassified

See 4 more Smart Citations

The Distribution of Hepatitis C Virus Genotypes in Patients with Chronic Hepatitis C Infection

Kırdar¹,

Yaşa²,

Aydın³

et al. 2015

meandros

View full text Add to dashboard Cite

Amaç: Hepatit C virüsü (HCV), kronik hepatit, siroz ve hepatosellüler karsinoma yol açarak dünya çapında önemli bir sağlık sorunu olmaktadır. Dizi analizi çalışmaları ile HCV'nin 7 genotipi ve 100'den fazla alt tipi olduğu ortaya konmuştur. HCV genotip 1'in genotip 2 ve 3'e göre daha ciddi hastalık yaptığı ve tedaviye kalıcı yanıtın daha az olduğu bilinmektedir. Bu çalışmada, kronik hepatit C hastalarında genotip dağılımının belirlenmesi amaçlanmıştır. AbstractObjective: Hepatitis C virus (HCV) infection represents a major public health problem worldwide. HCV can cause chronic hepatitis infection which may ultimately result in cirrhosis and hepatocellular carcinoma. Seven major genotypes and more than 100 subtypes of HCV are shown by sequence analysis. Genotype 1 is associated with more severity of liver disease than genotypes 2 and 3 and sustained response to

show abstract

Section: Introductionunclassified

“…Tedaviye yanıt kriteri olarak ve tedavi süresinin belirlenmesinde HCV-RNA düzeyleri ve HCV genotipleri yol göstericidir (1).…”

Section: Introductionunclassified

See 3 more Smart Citations

The Distribution of Hepatitis C Virus Genotypes in Patients with Chronic Hepatitis C Infection

Kırdar¹,

Yaşa²,

Aydın³

et al. 2015

meandros

View full text Add to dashboard Cite

show abstract

Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease

Bokharaei‐Salim

Keyvani

Monavari

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

The diagnosis of cryptogenic liver disease is made when after extensive evaluations, recognizable etiologies of chronic liver disease are excluded. In this study, the presence of hepatitis C virus (HCV) RNA was tested in peripheral blood mononuclear cells (PBMCs) taken from Iranian patients who although were found negative for plasma HCV RNA and anti-HCV antibodies, suffered from chronic liver disease of unknown etiology. From September 2007 to March 2010, 69 patients from Tehran with chronic liver disease of unknown etiology who were referred to our center were enrolled in the present study. PBMCs were isolated from 10 mL peripheral blood specimens. HCV-RNA status was tested in plasma and PBMCs samples by reverse-transcription polymerase chain reaction (RT-PCR). HCV-RNA was detected in HCV-positive PBMCs specimens by RT-PCR method. HCV genotypes were subsequently analyzed in HCV-positive samples using restriction fragment length polymorphism (RFLP) assay; then HCV genotypes were confirmed by sequencing of 5' non-coding fragments after cloning PCR products into pJET1.2/blunt cloning vector. HCV-RNA was detected in PBMCs specimens belonging to 7 (10%) out of 69 patients. Genotyping of the HCV-RNA isolated from PBMCs showed that 3 (43%) patients with occult HCV infection had genotype 1b, 2 (29%) had genotype 1a, and another 2 (29%) had genotype 3a. The results of this study suggest that patients with chronic liver disease of unknown etiology may have occult HCV infection in the absence of anti-HCV antibodies and plasma HCV-RNA. It has been suggested that in the absence of liver biopsy specimens, analysis of PBMC sample for HCV-RNA would be informative.

show abstract

Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders

Farahani

Bokharaei‐Salim

Ghane

et al. 2012

Journal of Medical Virology

View full text Add to dashboard Cite

Occult HCV infection is a form of chronic HCV infection characterized by absence of detectable anti-HCV antibodies or plasma HCV-RNA but presence of HCV-RNA in liver biopsy and/or peripheral blood mononuclear cells (PBMCs). The aim of this study was to determine the presence of HCV-RNA in PBMCs of patients with lymphoproliferative disorders. One hundred and four consecutive patients with lymphoproliferative disorders admitted to Firouzgar Hospital from January 2010 to March 2011 were recruited in this cross-sectional study. A 6-ml sample of whole blood was taken from the patients, the total RNA was extracted from the samples after the separation of plasma and PBMCs. The HCV-RNA of the samples was amplified by reverse transcriptase-nested polymerase chain reaction (RT-nested PCR). The HCV genotypes of the positive samples were tested using the INNO-LiPA™ HCV II kit, and the HCV genotypes were then confirmed by sequencing of the 5'-UTR fragments after the PCR products were cloned into a pJET1.2/blunt cloning vector. The mean age of the patients was 48.3 ± 1.76 years (range: 16-83). HCV-RNA was found in PBMCs from 2 (1.9%) of the 104 patients. Genotyping showed that the patients were infected with HCV subtype 1a. One patient suffered non-Hodgkin's lymphoma and the other suffered chronic lymphocytic leukemia. Patients with lymphoproliferative disorders with negative anti-HCV antibodies and negative plasma HCV-RNA may have occult HCV infection. Therefore, in the absence of a liver biopsy, the testing of PBMCs for the detection of genomic HCV-RNA may be beneficial.

show abstract

Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection

Abstract: Our study shows that a significant proportion of patients with chronic hepatitis C are affected by multiple HCV genotypes which may not be detectable only in serum of patients.

Cited by 28 publications

References 43 publications

The Distribution of Hepatitis C Virus Genotypes in Patients with Chronic Hepatitis C Infection

The Distribution of Hepatitis C Virus Genotypes in Patients with Chronic Hepatitis C Infection

Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease

Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders

Contact Info

Product

Resources

About